Logo image
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy
Journal article   Peer reviewed

Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy

B.L. Mangan, R.K. McAlister, J.M. Balko, D.B. Johnson, J.J. Moslehi, A. Gibson and E.J. Phillips
British Journal of Clinical Pharmacology, Vol.86(9), pp.1778-1789
2020
url
Link to Published Version *Subscription may be requiredView

Abstract

Immune checkpoint inhibitors have emerged as a revolutionary treatment option for patients with various types of malignancy. Although these agents afford a significant improvement in outcomes for melanoma and other previously untreatable malignancies, their novel mechanism of action may predispose patients to immune‐related adverse effects (irAEs). In the tumour neoantigen environment, these irAEs are due to the activation of the immune system by the blockade of suppressive checkpoints, leading to increases in T‐cell activation and proliferation. IrAEs have been reported in almost any organ and at any point in time, even months to years after discontinuation of therapy. Certain populations with distinct physiological changes, genetic risk factors, and specific antigen exposures may be more highly predisposed to develop irAEs. This review discusses the incidence and mechanisms of irAEs and the relationship between host factors and irAE occurrence.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.6 Immunology
1.6.214 Checkpoint Inhibition
Web Of Science research areas
Pharmacology & Pharmacy
ESI research areas
Pharmacology & Toxicology
Logo image